Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

Adherence to EMA Directive 2010/63/EU for NHP Welfare in Preclinical Gene Therapy Trials

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Adherence to EMA Directive 2010/63/EU for NHP Welfare in Preclinical Gene Therapy Trials

Adherence to EMA Directive 2010/63/EU for NHP Welfare in Gene Therapy Studies

CELL & GENE | RNA | BIOLOGICS

Ethical Rigor, Translational Clarity.

Adherence to EMA Directive 2010/63/EU for non-human primate (NHP) studies is a scientific and ethical requirement for gene therapy programs targeting the European market. Proper implementation of this directive ensures the generation of high-fidelity, reproducible data by minimizing physiological stress, a confounding variable that can obscure observations of a therapeutic’s effects. This approach directly supports robust regulatory submissions and de-risks clinical translation.

    How does EMA Directive 2010/63/EU specifically impact NHP study design for AAV gene therapies?

    A: The directive mandates stringent protocols for housing, enrichment, and handling that directly influence the physiological baseline of the animals. For AAV studies, this stable baseline is necessary for accurately assessing behavioral and physiological responses, as stress-induced factors can alter study outcomes.

    What are the primary welfare endpoints monitored under this directive?

    A: Monitoring extends beyond basic health checks to include behavioral assessments, species-specific enrichment engagement, and physiological markers of well-being. Endpoints are prospectively defined and include measures to identify and alleviate pain, suffering, and distress, with clear humane endpoint criteria.

    How does Franklin Biolabs integrate the “3Rs” (Replacement, Reduction, Refinement) into NHP protocols?

    A: We apply the 3Rs framework under AAALAC and USDA guidelines. Replacement is addressed through extensive in vitro and ex vivo modeling prior to NHP selection. Reduction is achieved via advanced statistical design and multi-modal endpoint analysis to maximize data acquisition from each animal. Refinement is continuous, involving minimally invasive techniques and optimized husbandry practices.

    What documentation is required to demonstrate compliance for an EMA submission?

    A: A comprehensive record must detail the ethical review process, the justification for NHP use, all procedures performed, daily welfare monitoring logs, environmental enrichment schedules, and any adverse events with corresponding interventions. Such comprehensive records are a core component of the nonclinical data package.

A scientist in a modern lab analyzes colorful DNA sequencing data on a tablet.

The Regulatory Framework for Scientific Validity

For gene therapy developers targeting EMEA, compliance with Directive 2010/63/EU is foundational to program success. The directive establishes a comprehensive framework for the protection of animals used for scientific purposes, with specific provisions for NHPs that recognize their cognitive and social complexity.

Executing studies within this framework enhances data integrity and scientific validity. By standardizing conditions and minimizing distress through sophisticated enrichment and handling protocols, we reduce the biological variability that can mask subtle but significant findings related to an investigational therapeutic.

Welfare Science and Data Integrity in NHP Models

The translational value of NHP models depends on their ability to predict human outcomes. This predictive power can be compromised by physiological variables unrelated to the investigational therapeutic. For AAV vectors, understanding species-specific biological factors is a primary objective of NHP studies.

As demonstrated in AAV9 engineering research (PMID: 39001819), subtle biological differences between species can significantly alter therapeutic responses. An animal under physiological stress may present confounding data that obscures these precise interactions. Rigorous welfare standards create the stable biological environment required to detect these species-specific responses, ensuring the NHP data accurately informs clinical strategy.

A close-up of a multi-channel pipette dispensing liquid into a microplate in a laboratory setting, with a blue color overlay.

A close-up, detailed shot of a Sartorius Stedim Biotech BIOSTAT STR® single-use bioreactor in a laboratory setting.

Animal Welfare and The 3Rs

  • Replacement: Utilizing validated in vitro assays and computational models to answer key questions before initiating in vivo work.

  • Reduction: Employing advanced imaging and analytical techniques to maximize the data derived from the minimum number of animals required for statistical power.

  • Refinement: Continuously improving housing, handling, and procedural techniques to enhance animal well-being throughout the study lifecycle.

*

GxP-Compliant Execution for Regulatory Success

All NHP studies are conducted within our >100,000 sq ft facility under strict GxP conditions. This ensures that all welfare and scientific data are captured with the integrity required for regulatory submission to the EMA and other global health authorities. Our disciplined approach has contributed to a 100% IND/CTA success rate for our partners since 2019 (the Franklin Biolabs brand launched in 2024), consistently delivering robust preclinical data packages on an 18-24 month IND timeline. This GxP-compliant operational structure supports the generation of reliable data for accelerated program timelines.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities